Drug intelligence / Profile preview

flucloxacillin (Navesta Pharmaceuticals)

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Uniflox is a brand name for flucloxacillin, a narrow-spectrum beta-lactam antibiotic of the penicillin class, specifically categorized as a penicillinase-resistant penicillin. Manufactured by Navesta Pharmaceuticals, it is indicated for the treatment of bacterial infections caused by Gram-positive organisms, particularly penicillinase-producing staphylococci. Flucloxacillin exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the transpeptidation enzymes responsible for cross-linking peptidoglycan chains, thereby disrupting cell wall synthesis and leading to bacterial cell lysis. Uniflox is typically administered orally and is available in a 500 mg capsule dosage form.

Brand names
Uniflox
Other names
floxacillin
02

Targets

HLA-B*57:01 (Human leukocyte antigen B*57:01)PBP2x (Penicillin-binding protein 2x)

Beyond the preview

Go deeper on flucloxacillin (Navesta Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on flucloxacillin (Navesta Pharmaceuticals).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call